Patented Compound Delivers Predicted Heart Health Benefits
CHICAGO, IL – SourceOne™ Global Partners has announced the completion of the final phase of a three-phase clinical trial on its signature proprietary cardiovascular wellness compound, Sytrinol™, and the results are consistent with compelling earlier findings.
The Phase III arm is a critically important element to the full long-term Sytrinol™ trial; many compounds have only one phase and some are not placebo controlled. This study is a twelve week, double-blind, crossover design, randomized trial of 120 moderately hypercholesterolemic men and women.
In phase I, the trial subjects consumed either 150mg of Sytrinol™ or a placebo twice daily for twelve weeks; blood samples were drawn and analyzed at baseline, four, eight and 12 weeks. In Phase II, the trial was a controlled washout period for four weeks for both groups. Phase III of the trial was a crossover design where the group that initially took the placebo, now consumed 150mg of Sytrinol™ twice daily for 12 weeks, and the group consuming Sytrinol™ was now given the placebo. The same statistical blood analyses were performed as in phase I. The crossover design clinical trial is the highest standard for validating the efficacy of a bioactive compound.
“This multiphase clinical trial underscores previous research demonstrating the value Sytrinol™ delivers to consumers managing healthy cholesterol levels naturally, as part of a cardiovascular wellness plan,” says Jesse Lopez, founder, president and CEO of SourceOne™ Global Partners. “Crucial is the element of statistically significant repeatability that further galvanizes the authenticity of Sytrinol™ as the foundation of all heart health formulas.”
Sytrinol™, a patented proprietary formula derived from citrus and palm fruit extracts, is composed of polymethoxylated flavones and tocotrienols. Multiple clinical trials have demonstrated that SytrinolÔ acts synergistically to significantly improve total cholesterol, LDL cholesterol and triglycerides by up to 30%, 27% and 33%, respectively, compared to placebo.
Additionally, Sytrinol™ is a powerful antioxidant with numerous heart health benefits including playing a significant role as an anti-inflammatory. Other heart health parameters being studied include C-reactive protein (CRP), apolipoprotein AI, and apolipoprotein B. Recent research is establishing that inflammation may cause C-reactive protein (CRP) to be produced in the body and is considered a reliable marker for sudden heart attack. Apolipoprotein AI is a major component of HDL and is associated with a decreased risk of cardiovascular disease, while apolipoprotein B is a major component of LDL and is associated with an increased risk of cardiovascular disease. Sytrinol™ contains specific compounds that are suggested to positively affect these reliable predictors of cardiovascular disease; this data is being compiled throughout the three phases of this study. Unlike other cholesterol targeted supplements, Sytrinol™ is not diet specific and has no known side effects.* SourceOne owns the exclusive worldwide license for the intellectual property associated with Sytrinol™.
SourceOne™ Global Partners represents a new breed of ingredient supplier, partnering with manufacturing clients to introduce powerfully branded, science-driven products to market with a unique product positioning and compelling consumer presence. SourceOne was conceived as a company whose core competence is to integrate legitimate science with strong trade and consumer branding. SourceOne™ Global Partners cultivates relationships with leading suppliers worldwide to source and offer patented ingredients supported by proprietary science as part of a turnkey marketing program that dramatically increases the odds for marketing success.
*Sytrinol™: A new cholesterol-lowering product. Najla Guthrie & Elzbieta Kurowska, WorldNutra Third Annual International Conference and Exhibition on Nutraceuticals and Functional Foods, San Diego, CA November, 2002.
NOTE: A full presentation of the research findings and their relevancy to cardiovascular wellness will be presented at Experimental Biology in San Diego, CA in April 2005. Please call Begüm Tümer at SourceOne for more information (312) 321-8222 or Kristin Reynolds at KGK Synergize (519) 438-9374 ext. 222.